We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- First publication
- Gene mutation
- Consequence of sickling
- The kidney is a very vascular organ
- Renal blood flow
- Nitric oxide
- Renal vasculature in health & disease
- Clinical manifestations (1)
- Clinical manifestations (2)
- Clinical manifestations (3)
- Clinical manifestations (4)
- Prevalence of microalbuminuria
- Progression
- Hemolytic parameters
- SC & alpha thalassemia
- Monitoring patients for SCN
- Recommended investigations for proteinuria
- Recommended investigations for haematuria
- Renal function
- Who should be referred to a nephrologist?
- The example of Mrs. O (1)
- The example of Mrs. O (2)
- Mrs. O - Biopsy
- IgA mesangial deposition
- Sickle cell nephropathy management
- Evidence for use of ACEI & ARB in SCN
- Response to ACE inhibition
- Hydroxyurea & exchange transfusion
- The example of Mr. O (1)
- The example of Mr. O (2)
- The example of Mr. O (3)
- Outcome of sickle cell anemia
- Transplantation for SCN
- Conclusion
Topics Covered
- The underlying pathophysiology of sickle cell nephropathy
- The common clinical manifestations of the disease
- Early screening and management
- Management of advanced chronic kidney disease due to sickle cell nephropathy
- Outcomes following kidney transplantation in patients with sickle cell disease
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Sharpe, C. (2016, October 31). Renal complications of sickle cell disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/BQLT2872.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Claire Sharpe has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: The Kidney in Health and Disease
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Claire Sharpe.
I'm a consultant nephrologist
at King's College Hospital
and a senior lecturer
at King's College, London.
I have been interested
in Sickle cell disease in the kidney
since 2004,
when I've started a joint sickle cell
and kidney clinic
along with the hematologists
at King's College Hospital.
I'm going to talk a little bit
about pathophysiology of sickle cell
and kidney complications,
and talk about
the clinical manifestations.
0:31
The first person
to describe sickle cell disease
in the western literature
was James Herrick,
who was working in Boston around 1910.
He was looking after a young man
from Grenada,
who traveled to United States
to do a dental degree.
This young man
had had a sickly childhood,
and when he arrived in America,
he was suffering with leg ulcers.
This paper very clearly describes
both the history
and the clinical examination
of this man.
And of note, James Herrick brings out
that he had increased urine volume
of low specific gravity,
which contained
a distinct trace of serum albumin.
And this very much sums up
the sickle cell nephropathy,
which we recognize
in many of our patients today.
1:18
The underlying genetic mutation
was first described in Cambridge
by Vernon Ingram in 1957.
A single point mutation
results in a replacement
to the glutamine
with a valine at the six amino acid,
and the beta-chain of adult hemoglobin.
This results in the beta hemoglobin
becoming less soluble,
particularly under hypoxic
and acidotic conditions.
This results in polymerization
of the beta hemoglobin
which can form
these rope like structures
seen here in this middle picture.
These structures make the red blood cell
rigid and undeformable
and it takes on this
characteristic sickling shape.
This polymerization sickling
is initially reversible.
However, after many cycles of sickling,
the red blood cell becomes
irreversibly sickled,
and then can spill over
into the peripheral circulation
that's seen on the right.
This is what James Herrick noted
and more gave the disease its name.